Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database.

Saved in:
Bibliographic Details
Title: Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database.
Authors: Dreikhausen L; Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. lena.dreikhausen@umm.de., Olkus A; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.; German Cancer Research Center (DKFZ) Heidelberg, Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany.; Liver Cancer Center Heidelberg, Heidelberg, Germany., Dill M; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.; German Cancer Research Center (DKFZ) Heidelberg, Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany.; Liver Cancer Center Heidelberg, Heidelberg, Germany., Springfeld C; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Heumann P; Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany., Schulte N; Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Atanasova K; Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Ebert MP; Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; DKFZ Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.; Mannheim Cancer Center, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany., Letsch A; Department of Internal Medicine II, University Hospital Center Schleswig-Holstein, Kiel, Germany.; University Cancer Center Schleswig-Holstein, Kiel, Germany., Wandmacher AM; Department of Internal Medicine II, University Hospital Center Schleswig-Holstein, Kiel, Germany.; University Cancer Center Schleswig-Holstein, Kiel, Germany.; Group of Inflammatory Carcinogenesis, Institute for Experimental Cancer Research, University Hospital Schleswig-Holstein (UKSH), Kiel University, Kiel, Germany., Zhan T; Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Tianzuo.zhan@umm.de.; DKFZ Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. Tianzuo.zhan@umm.de.; Mannheim Cancer Center, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Tianzuo.zhan@umm.de.; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany. Tianzuo.zhan@umm.de.
Source: Targeted oncology [Target Oncol] 2026 May; Vol. 21 (3), pp. 411-420. Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article; Multicenter Study; Comparative Study
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1776-260X
DOI:10.1007/s11523-026-01211-6